The next frontier in obesity drugs: lasting weight loss

The next frontier in obesity drugs: lasting weight loss is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-10-06

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Source: PharmaVoice